SMS reminders to improve the uptake and timeliness of the primary immunisation series in infants: a multi-centre randomised controlled trial.


Journal

Communicable diseases intelligence (2018)
ISSN: 2209-6051
Titre abrégé: Commun Dis Intell (2018)
Pays: Australia
ID NLM: 101735394

Informations de publication

Date de publication:
19 May 2022
Historique:
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

Immunisation timeliness continues to present challenges to achieving optimal vaccine coverage in infancy, particularly in disadvantaged groups and Australian First Nations infants. We aimed to determine whether a tailored, educational SMS reminder improves the timeliness of immunisation in infants up to seven months of age. A pragmatic, three-arm, parallel-group, randomised controlled trial of immunisation reminders was conducted in two First-Nations-specific primary health care centres and two public hospital antenatal clinics in South East Queensland, Australia. Live-born infants of mothers enrolled during pregnancy were randomised at birth and followed to eight months of age. One group received a simple SMS reminder at two weeks before, the week of, and two weeks after the due date for immunisation at two, four and six months of age. The second group received a tailored SMS with an educational message at two weeks before and on the date immunisations were due; those not immunised two weeks following the due date were offered support to immunise the baby. Controls received no intervention or contact until the baby turned seven months of age. The primary outcome was the proportion of infants age-appropriately vaccinated at seven months of age as recorded on the Australian Immunisation Register. Secondary outcomes included vaccination status at three and five months of age. Between 30 May 2016 and 24 May 2018, one hundred and ninety-six infants (31% First Nations infants) were randomised. At seven months of age, 54/65 (83.1%) infants in the educational SMS ± additional support group (ESMS±S) were age-appropriately immunised, compared to 45/64 (70.3%) in the simple SMS group and 45/67 (67.2%) in controls. Differences were most marked at five months of age: ESMS±S 95.5%; simple SMS 73.4%; controls 75.8%. The difference between the ESMS±S group and the other two groups at seven months of age was no longer apparent when those who received additional support beyond the SMS were assumed to have not been vaccinated if that support had not been received. A tailored SMS reminder system using an educational message and with provision of additional support to mothers is more effective in improving immunisation timeliness in infants at three and five months of age than a simple message and no intervention. The additional support was required at seven months of age in order to achieve higher coverage in the ESMS±S group.

Sections du résumé

Background UNASSIGNED
Immunisation timeliness continues to present challenges to achieving optimal vaccine coverage in infancy, particularly in disadvantaged groups and Australian First Nations infants. We aimed to determine whether a tailored, educational SMS reminder improves the timeliness of immunisation in infants up to seven months of age.
Methods UNASSIGNED
A pragmatic, three-arm, parallel-group, randomised controlled trial of immunisation reminders was conducted in two First-Nations-specific primary health care centres and two public hospital antenatal clinics in South East Queensland, Australia. Live-born infants of mothers enrolled during pregnancy were randomised at birth and followed to eight months of age. One group received a simple SMS reminder at two weeks before, the week of, and two weeks after the due date for immunisation at two, four and six months of age. The second group received a tailored SMS with an educational message at two weeks before and on the date immunisations were due; those not immunised two weeks following the due date were offered support to immunise the baby. Controls received no intervention or contact until the baby turned seven months of age. The primary outcome was the proportion of infants age-appropriately vaccinated at seven months of age as recorded on the Australian Immunisation Register. Secondary outcomes included vaccination status at three and five months of age.
Results UNASSIGNED
Between 30 May 2016 and 24 May 2018, one hundred and ninety-six infants (31% First Nations infants) were randomised. At seven months of age, 54/65 (83.1%) infants in the educational SMS ± additional support group (ESMS±S) were age-appropriately immunised, compared to 45/64 (70.3%) in the simple SMS group and 45/67 (67.2%) in controls. Differences were most marked at five months of age: ESMS±S 95.5%; simple SMS 73.4%; controls 75.8%. The difference between the ESMS±S group and the other two groups at seven months of age was no longer apparent when those who received additional support beyond the SMS were assumed to have not been vaccinated if that support had not been received.
Discussion UNASSIGNED
A tailored SMS reminder system using an educational message and with provision of additional support to mothers is more effective in improving immunisation timeliness in infants at three and five months of age than a simple message and no intervention. The additional support was required at seven months of age in order to achieve higher coverage in the ESMS±S group.

Identifiants

pubmed: 35591748
doi: 10.33321/cdi.2022.46.15
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Commonwealth of Australia CC BY-NC-ND.

Auteurs

Kerry-Ann F O'Grady (KF)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Michelle Kaus (M)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Lee Jones (L)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Gary Boddy (G)

Communicable Diseases Branch, Queensland Health, Herston, Queensland, Australia.

Sheree Rablin (S)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Jack Roberts (J)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Daniel Arnold (D)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Sarah Parfitt (S)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Renee Johnston (R)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Kerry K Hall (KK)

First Peoples Health Unit, Griffith University, Southport, Queensland, Australia.

Sallyanne Le Gros-Wilson (S)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Kaley Butten (K)

Australian Centre for Health Services Innovation@Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.
Australian eHealth Research Centre, CSIRO, Herston, Queensland, Australia.

Maree Toombs (M)

Faculty of Medicine & Biomedical Sciences, The University of Queensland, Herston, Queensland, Australia.
Carbal Health Services, Toowoomba, Queensland Australia.

Stephen B Lambert (SB)

Communicable Diseases Branch, Queensland Health, Herston, Queensland, Australia.
National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH